A Review on Development and Validation of Analytical Method for Simultaneous Estimation of Formoterol Fumarate Dehydrate and Fluticasone Propionate from Bulk and Dry Powder Inhaler Formulation

Abstract

To compare the cost, therapy adherence, and related healthcare utilisation of formoterol fumarate dihydrate and fluticasone propionate, two combinations inhaled corticosteroid/long acting beta-agonist products approved for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. The UV- approach for formoterol fumarate dihydrate (FFD) and fluticasone propionate (FP) is a simultaneous equation technique, an absorbance ration method, and a first order derivative method. The wavelengths of FFD and FP are 236nm and 215nm, respectively, and the overlap of FFD and FP is 233nm. The method may be used to routinely analyse formoterol fumarate dihydrate and fluticasone propionate in dry powder inhalation formulations. Early dry powder inhalers (DPIs) were created for modest medication dosages in the treatment of asthma and COPD. This study used carrier-based formulations and did not employ efficient dispersion principles. As a result, partial engineering and powder processing are being used more frequently to obtain acceptable lung deposition with this poorly constructed inhaler.